The main vaccine manufacturers will present their vaccine strategy to the Technical Commission on Vaccinations at the premises of the High Authority for Health (HAS), in Paris, Tuesday, December 17.
Established in 2017, the Technical Commission on Vaccinations (CTV) is a national technical advisory group on immunizations (NITAG), expert-led groups that evaluate the pharmaceutical industry’s vaccination programs.
Giants Pfizer, Sanofi, Moderna, GSK and Novavax confirmed to Euractiv that they will attend the commission meeting in Paris on Tuesday.
AstraZeneca, MSD and BioNTech, expected to participate in the meeting, had not responded to our requests at the time of publication of this article.
« We are excited about this meeting. Indeed, Moderna currently has more than 40 programs under development in its pipeline and intends, globally, to launch 10 products in the next 3 years. », Moderna told EURACTIV.
Each laboratory will present its vaccines under development, the different therapeutic areas and indications, as well as the planned dates for submitting them to the European Medicines Agency (EMA).
“From one year to the next, they are not always the same laboratories: sometimes they are big ones, sometimes small ones. This allows the CTV to anticipate its work program,” explained the HAS to EURACTIV.
The American pharmaceutical company Novavax will present its combined vaccine against Covid19 and influenza, as well as its candidate for stand-alone influenza vaccines.
France’s Sanofi is currently working on a dozen vaccines, including mRNA flu vaccines, a rabies vaccine and a yellow fever vaccine.
For its part, Moderna is working on vaccines intended to fight respiratory diseases and latent viruses, such as herpes, which are most often dormant but sometimes reactivate.
Currently, 98 vaccines are being developed by member companies of Vaccines Europe, which represents vaccine manufacturers in Europe.
Almost all countries in Europe have NITAGs, such as the Joint Committee on Vaccination and Immunization (JCVI) in the United Kingdom, the Finnish Institute for Health and Welfare (THL), and the Standing Committee on Vaccination ( STIKO) in Germany.
“The CTV exchanges with the other GTCVs on the evaluation strategies and recommendations in force”, specifies the HAS, while the annual meeting of European GTCVs was held in Stockholm in November.
